Shun Lu Selected Research

Small Interfering RNA (siRNA)

11/2023	[Retracted] Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo‑keto reductase family 1 member B10.
9/2021	Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma.
1/2019	Inhibition of ZIP4 reverses epithelial-to-mesenchymal transition and enhances the radiosensitivity in human nasopharyngeal carcinoma cells.
2/2018	Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10.
1/2017	FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells.
1/2013	Metformin inhibits esophagus cancer proliferation through upregulation of USP7.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shun Lu Research Topics

Disease

164	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2024 - 02/2007
127	Neoplasms (Cancer) 05/2024 - 11/2008
66	Lung Neoplasms (Lung Cancer) 05/2024 - 12/2003
32	Disease Progression 05/2024 - 08/2011
26	Neoplasm Metastasis (Metastasis) 12/2023 - 09/2008
22	Adenocarcinoma of Lung 01/2023 - 09/2008
15	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2023 - 08/2015
11	Exanthema (Rash) 11/2022 - 08/2011
10	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2024 - 01/2015
10	Carcinoma (Carcinomatosis) 12/2022 - 11/2018
9	Brain Neoplasms (Brain Tumor) 05/2023 - 11/2015
9	Diarrhea 01/2023 - 01/2017
9	Carcinogenesis 04/2022 - 10/2013
7	Neutropenia 04/2023 - 08/2011
6	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2024 - 01/2020
6	Stomatitis 12/2022 - 02/2014
6	Acne Vulgaris 01/2018 - 02/2014
5	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 11/2013
5	Adenocarcinoma 01/2022 - 11/2008
5	Thrombocytopenia (Thrombopenia) 01/2018 - 09/2008
4	Squamous Cell Carcinoma of Head and Neck 01/2024 - 01/2019
4	Vomiting 01/2023 - 02/2014
4	Pain (Aches) 12/2022 - 01/2015
3	Osteonecrosis (Kienbock's Disease) 11/2023 - 01/2023
3	Inflammation (Inflammations) 11/2023 - 06/2021
3	Hypertriglyceridemia 05/2023 - 11/2018
3	Anemia 04/2023 - 10/2018
3	Drug-Related Side Effects and Adverse Reactions 01/2023 - 06/2012
3	Dyspnea (Shortness of Breath) 03/2022 - 01/2018
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 05/2020
3	Interstitial Lung Diseases (Interstitial Lung Disease) 06/2021 - 05/2012
3	Leukopenia 01/2021 - 07/2010
3	Osteosarcoma (Osteogenic Sarcoma) 01/2020 - 01/2015
3	Infections 01/2017 - 01/2010

Drug/Important Bio-Agent (IBA)

43	ErbB Receptors (EGF Receptor)IBA 03/2024 - 04/2009
29	Tyrosine Kinase InhibitorsIBA 01/2024 - 08/2011
24	PlatinumIBA 04/2024 - 06/2009
22	Biomarkers (Surrogate Marker)IBA 01/2024 - 04/2009
20	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2019
18	AfatinibIBA 01/2022 - 02/2014
17	Cisplatin (Platino)FDA LinkGeneric 01/2024 - 02/2014
15	NivolumabIBA 05/2024 - 01/2019
15	Proteins (Proteins, Gene)FDA Link 01/2024 - 02/2013
15	Gefitinib (Iressa)FDA Link 10/2023 - 08/2011
14	CrizotinibIBA 12/2023 - 01/2016
13	osimertinibIBA 03/2024 - 01/2018
13	Pemetrexed (MTA)FDA Link 02/2024 - 10/2009
13	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2021 - 08/2011
11	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2013
10	Anaplastic Lymphoma KinaseIBA 08/2022 - 05/2015
9	Docetaxel (Taxotere)FDA Link 04/2024 - 06/2009
9	Gemcitabine FDA Link 01/2019 - 08/2011
8	Phosphotransferases (Kinase)IBA 01/2024 - 05/2015
7	B7-H1 AntigenIBA 11/2023 - 01/2019
7	Carboplatin (JM8)FDA LinkGeneric 11/2023 - 08/2011
6	Small Interfering RNA (siRNA)IBA 11/2023 - 01/2013
6	1- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA 01/2023 - 01/2019
5	IpilimumabIBA 02/2024 - 01/2021
5	Bevacizumab (Avastin)FDA Link 01/2023 - 07/2015
5	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 03/2008
5	Alanine Transaminase (SGPT)IBA 11/2022 - 08/2011
5	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2013
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 04/2009
4	atezolizumabIBA 04/2024 - 01/2021
4	alectinibIBA 04/2024 - 11/2021
4	Messenger RNA (mRNA)IBA 01/2024 - 10/2013
4	Etoposide (VP 16)FDA LinkGeneric 11/2023 - 01/2015
4	RNA (Ribonucleic Acid)IBA 10/2023 - 01/2021
4	selpercatinibIBA 10/2023 - 01/2022
4	LigandsIBA 03/2022 - 01/2013
4	Transcription Factors (Transcription Factor)IBA 01/2022 - 01/2006
4	Circulating Tumor DNAIBA 01/2022 - 01/2019
4	Paclitaxel (Taxol)FDA LinkGeneric 12/2019 - 09/2008
4	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 09/2019 - 01/2017
3	InterferonsIBA 05/2024 - 01/2014
3	Indicators and Reagents (Reagents)IBA 01/2024 - 01/2019
3	CytokinesIBA 01/2024 - 01/2015
3	brigatinibIBA 12/2023 - 11/2021
3	tislelizumabIBA 11/2023 - 05/2021
3	Peptides (Polypeptides)IBA 11/2023 - 06/2012
3	Biosimilar PharmaceuticalsIBA 01/2023 - 12/2019
3	sintilimabIBA 01/2023 - 01/2022
3	pyrotinibIBA 01/2022 - 09/2021
3	aumolertinibIBA 01/2022 - 06/2021
3	EnzymesIBA 11/2021 - 05/2011
3	AntibodiesIBA 09/2021 - 12/2019
3	HMPL-013IBA 02/2021 - 01/2018
3	Cell-Free Nucleic AcidsIBA 01/2021 - 01/2017
3	Protein Isoforms (Isoforms)IBA 12/2019 - 12/2013

Therapy/Procedure

73	Drug Therapy (Chemotherapy) 05/2024 - 02/2007
73	Therapeutics 02/2024 - 12/2003
33	Immunotherapy 05/2024 - 06/2018
15	Radiotherapy 04/2024 - 11/2012
5	Adjuvant Chemotherapy 07/2023 - 06/2009
5	Precision Medicine 01/2023 - 01/2017
4	Chemoradiotherapy 01/2023 - 12/2016
4	Neoadjuvant Therapy 01/2023 - 01/2020
3	Oral Administration 11/2023 - 08/2015
3	Lymph Node Excision (Lymph Node Dissection) 11/2022 - 06/2009
3	Pneumonectomy (Lung Volume Reduction) 01/2017 - 06/2009